Roche falls four places to seventh on the 2026 Global Pharmaceutical Innovation Index and three places to seventh on the Invention Index. Group sales, core operating profit and net income all increased. The company continued its pipeline productivity, including 10 potential new medicines entering late-stage development and twelve positive pivotal readouts.

In oncology, Roche delivered several important advances. Phase 3 lidERA data showed that giredestrant reduced the risk of invasive disease recurrence or death by 30% versus standard endocrine therapy in early breast cancer, while evERA demonstrated
a 44% reduction in progression or death overall and 62% in ESR1-mutated advanced disease following CDK inhibitor therapy. In hematology, updated STARGLO results showed that overall survival more than doubled with Columvi (glofitamab) plus GemOx in relapsed or refractory diffuse large B-cell lymphoma, and Itovebi (inavolisib) secured European Commission approval in PIK3CA- mutated HR-positive, HER2-negative advanced breast cancer.